fbpx

Revitalist Provides Summary of 2021, Reporting Patient Visits of 5,000, a 128% Increase From 2020

Revitalist Lifestye And Weness LTD. (CNSX: CALM) is pleased to recap the milestones the Company reached in the calendar year 2021. The Company has significantly scaled its operations during 2021, ending the year with seven clinics and providing approximately 5,000 patient treatments which represented a 128% increase year over year.

(Graphic: Business Wire) – Revitalist Chart

Noteworthy events for Revitalist in 2021 are summarized below under the respective headings. Please note that as a summary, this is not a comprehensive listing of the Company’s material events during each stated period. Complete disclosures of material events can be found on the Company’s SEDAR profile.

Patient Visits and Sales

Patient visits grew extensively in 2021, totaling approximately 5,000, up 128% from 2020. Sales for the year ended December 31, 2021, totaled approximately $2,200,000 (unaudited), representing a 110% increase year over year. Monthly visits are listed in the chart above.

Expansion

Revitalist commenced the year with one clinic under operation and ended with seven clinics across four states in the USA. January 2022 announcements included the opening of an additional clinic in Washington, D.C and the acquisition of clinic assets in Jacksonville, FL bringing the current total to nine clinics in 6 states. In addition, the Company executed agreements during 2021 securing options to open nine additional clinics in the USA for a period of three years. The Company also proudly announced patient coverage with Medicare and other insurance providers during the year as well as multiple strategic collaborations including US Veterans Affairs and clinical study partners.

Revitaland

Revitalist acquired a 60% interest in Revitaland Meta Tech Inc. to expand virtual clinics in the metaverse (“Revitaland”). Revitaland virtual clinics will allow patients to work with clinicians who aren’t in the same physical space in real time.

The Metaverse is an expansive network of 3D worlds and simulations that support continuity of identity, objects, history, payments, and entitlements, and can be experienced synchronously by an effectively unlimited number of users, each with an individual sense of presence.

Awards & Publications

Revitalist CEO Kathryn Walker received Microdose’s “Entrepreneur of the Year” award in November 2021 at Wonderland: Miami, the largest psychedelic medicine business event.

Clarus securities published coverage on the Company on October 25, 2021, with a speculative buy rating and a target of $1.50 per share. Revitalist was also featured by Forbes in an article highlighting the Company’s holistic approach to ketamine treatments and the vision of its founder, Kathryn Walker.

Equity Financing

Revitalist successfully raised over $11,000,000 in 2021, with it’s last $3,000,000 financing closing in November 2021 whereby H.C. Wainwright & Co. acted as the exclusive placement agent.

Capital Markets

On August 24, 2021, the Company commenced trading on the Canadian Securities Exchange under the symbol CALM. Shortly thereafter, Revitalist listed on the Frankfurt Stock Exchange and the OTCQB.

We are thrilled with the year we had in 2021 as we continued to form relationships with clinicians in the USA, provided 5,000 patient visits, and further optimized our operations to facilitate long-term growth. We ended the year with seven clinics and announced another two recently, bringing the total clinic count to nine. During the calendar year 2021, Revitalist also made several notable accomplishments in the capital markets, including our public listing on the Canadian Securities Exchange and raising over $11,000,000. On behalf of the Revitalist team, I express my utmost gratitude to everybody who contributed to our success over the past year as we continue to deliver exceptional patient care and corporate growth.

Revitalist CEO, Kathryn Walker

To view the original press release in its entirety click here


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More